Day One Biopharmaceuticals experienced impressive growth in 2025, with net product revenue reaching $155.4 million, a remarkable 172% year-over-year increase.
The projected 2026 U.S. net product revenue range for OJEMDA is between $225-$250 million, indicating sustained growth.
During the upcoming J.P. Morgan Healthcare Conference on January 12th, the company will disclose detailed progress and priorities for 2026.
2025 Net Product Revenue
Day One's net product revenue for 2025 surged to $155.4 million, marking a notable 172% increase compared to the previous year.
2026 Guidance
The company has forecasted a range of $225-$250 million for the U.S. net product revenue of OJEMDA in 2026, demonstrating a commitment to continued growth.
Corporate Priorities
Day One's key focuses for 2026 include enhancing persistency, driving new patient starts, expanding globally, and progressing pipeline programs to achieve strategic objectives.
Financial Position
As of December 31, 2025, Day One Biopharmaceuticals held approximately $441.1 million in cash, cash equivalents, and short-term investments, showcasing a strong financial position.
- Day One Biopharmaceuticals' exceptional financial and commercial performance in 2025 was primarily driven by the substantial growth in OJEMDA net product revenue, reflecting the company's effective product strategy and market penetration.
- The outlined initiatives for 2026 underscore Day One's strategic intent to broaden its market presence and advance critical programs, indicating a proactive approach to sustainable growth and innovation.
- Backed by a robust financial position and promising pipeline, Day One Biopharmaceuticals is positioned for prolonged success and advancement in the competitive biopharmaceutical landscape.
Day One's remarkable progress in 2025 not only signifies impressive growth but also lays a solid foundation for continued success in 2026. The company's strategic direction and commitment to innovation position it for further expansion and impact in the healthcare industry, showcasing potential for sustained value creation and market leadership.